Skip to main content
Blood Advances logoLink to Blood Advances
. 2017 Dec 8;1(Suppl 1):39–41. doi: 10.1182/bloodadvances.2017GS102602

Establishing a comprehensive diagnosis of primary immunodeficiency diseases

Eunice Sindhuvi Edison 1,, Anu Korula 1, Michael Lenardo 2, Vikram Mathews 1
PMCID: PMC6438296

  • The diagnosis of primary immunodeficiency disease (PIDD) is very important, because a correct and timely diagnosis can lead to lifesaving treatment and improvement in the quality of life for children in India.

  • Mutation analysis in PIDDs can help in definitive diagnosis (atypical presentations), carrier identification, genetic counseling, prenatal diagnosis, and prognosis (strong genotype-phenotype correlation).

  • Next-generation sequencing methods offer an unbiased genotype-based approach, which can facilitate quick and cost-effective molecular diagnostics.

  • >250 recognized PIDDs.

  • >300 genes involved.

  • There are very few centers in India offering a comprehensive diagnosis for PIDDs in India.

graphic file with name advances102602f1.jpg

graphic file with name advances102602f2.jpg

graphic file with name advances102602f3.jpg

Genetic variants identified in PIDD at CMC

  HLH X-SCID Hyperimmunoglobulin E Agammaglobulinemia CGD SIOD
STX11/PRF/UNC13D IL2RG STAT3 BTK CYBB
Patients, N 13 8 8 13 4 1
Mutations, N 4 3 2 5 0 0
Mutations PRF1 c.673 C>T (p.Arg225Tyr) c.314 A>G (Y105C) c.1144>T (p.R382W) g.27580 G>T* No mutation identified No mutation identified
PRF1 c.82 C>T (p.Gly28Arg) c.664 C>T (p.Arg222Cys) c.49delA
PRF1 c.133 G>T (p.Gly45Arg) c.66795_66798delTTTG
UNC13D c.147 T>C
c.1801_1807delTACAACG g.25633 G>A*

Training

Eunice Sindhuvi, Department of Haematology, Christian Medical College (CMC), Vellore, India, underwent training with Michael Lenardo at the Laboratory of Immunology, Molecular Development of the Immune System Section, National Institutes of Health, Bethesda, MD.

  • An extensive panel of markers was used to analyze different subsets of T and B cells using flow cytometry and assess their functions.

  • If a definite subgroup of PIDD was identified, direct sequencing of that particular gene was carried out to characterize the molecular defect. For example, patients with XMEN disease were screened for mutations in the MAGT1 gene.

Next-generation sequencing

  • Enrichment of exomic regions was done with an Ampliseq Exome kit.

  • DNA libraries were prepared and quantified with a bioanalyzer.

  • Sample analysis in the ion proton system.

  • Data generated were analyzed with Ion Reporter software and an in-house pipeline.

Work done at CMC

  • A comprehensive molecular diagnostic facility for PIDDs has been established at CMC. Antenatal diagnosis will be offered for couples with known molecular defects.

  • Molecular characterization of PIDDs is definitive, but is done only at a few selected centers in India.

  • Identifying the molecular basis will benefit patient families through carrier diagnosis and genetic counseling for affected families. The functional evaluation of novel genes will lead to a better understanding of our immune system.

Correspondence: Eunice Sindhuvi Edison, Department of Haematology, Christian Medical College, Vellore, India; e-mail: eunice@cmcvellore.ac.in.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

References

  • 1.Milner JD, Holland SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol. 2013;13(9):635-648. [DOI] [PubMed] [Google Scholar]
  • 2.Yu H, Zhang VW, Stray-Pedersen A, et al. Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. J Allergy Clin Immunol. 2016;138(4):1142-1151. [DOI] [PubMed] [Google Scholar]
  • 3.Stray-Pedersen A, Sorte HS, Samarakoon P, et al. Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017;139(1):232-245. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES